Association of OSMR Gene Variants rs2278329 and rs2292016 with Dermatomyositis and Systemic Lupus Erythematosus in Bulgarian Patients

J. Pozharashka; R. Bozhilova; M. Hristova; Z. Kamenarska; D. Kalinova; A. Vinkov; R. Kaneva; Z. Kolarov; L. Dourmishev

doi:10.2478/amb-2026-0039

Abstract

Introduction

The precise nature of dermatomyositis (DM) and systemic lupus erythematosus (SLE) is not yet fully understood, although it is recognized that various genetic, hormonal or external factors play a significant role in the onset of autoimmune processes. This study aims to explore the link between two specific genetic variants of the oncostatin M receptor (OSMR) – rs2278329 (Asp553Asn) and rs2292016 (-100G/T) – and the predisposition to DM and SLE in Bulgarian patients.

Materials and methods

A total of 126 individuals were included in the study – 62 patients with SLE, 64 with DM, and 95 healthy unrelated controls. Genotyping was performed using TaqMan assays.

Results

The analysis revealed that the minor allele frequency was low. None of the genetic variants investigated showed any significant correlation with SLE, DM, or clinical characteristics associated with these conditions.

Conclusions

Our findings suggest that none of the OSMR genetic variants investigated pose a significant risk for the development of dermatomyositis or systemic lupus erythematosus in Bulgarian patients.

References

Dourmishev LA. Inflammatory Myopathies with Cutaneous Involvement: from Diagnosis to Therapy. Folia Med (Plovdiv). 2017; 59(1):7-13.
Search in Google Scholar Back to article
Shirani Z, Kucenic MJ, Carroll CL, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol. 2004; 29(3):273-6.
Search in Google Scholar Back to article
Kim HJ. Pruritus in autoimmune connective tissue diseases. Ann Transl Med. 2021; 9(5):441.
Search in Google Scholar Back to article
Dourmishev L. Dermatomyositis associated with malignancy. 12 case reports. Adv Exp Med Biol. 1999; 455:193-9.
Search in Google Scholar Back to article
Luu X, Leonard S, Joseph KA. Dermatomyositis presenting as a paraneoplastic syndrome with resolution of symptoms following surgical management of underlying breast malignancy. J Surg Case Rep. 2015; 2015(7):rjv075.
Search in Google Scholar Back to article
Kamenarska ZG, Hristova MH, Vinkov AI, et al. Monoclonal Antibody Drugs for Systemic Lupus Erythematosus. Folia Med (Plovdiv). 2015; 57(2):89-92.
Search in Google Scholar Back to article
Hristova M, Dourmishev L, Kamenarska Z, et al. Role of the promoter polymorphism IL-6-174G/C in dermatomyositis and systemic lupus erythematosus. Biomed Res Int. 2013:315365.
Search in Google Scholar Back to article
Hams E, Colmont CS, Dioszeghy V, et al. Oncostatin M receptor-beta signaling limits monocytic cell recruitment in acute inflammation. J Immunol. 2008; 181(3):2174-80.
Search in Google Scholar Back to article
Tanaka M, Hara T, Copeland NG et al. Reconstitution of the functional mouse oncostatin M (OSM) receptor: molecular cloning of the mouse OSM receptor beta subunit. Blood. 1999; 93(3):804-15.
Search in Google Scholar Back to article
Isozaki O, Tsushima T, Miyakawa M, et al. Oncostatin M: a new potent inhibitor of iodine metabolism inhibits thyroid peroxidase gene expression but not DNA synthesis in porcine thyroid cells in culture. Thyroid. 1997; 7(1):71-7.
Search in Google Scholar Back to article
Klausen P, Pedersen L, Jurlander J, et al. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene. 2000; 19(32):3675-83.
Search in Google Scholar Back to article
Bachetti T, Rosamilia F, Bartolucci et al. The OSMR Gene Is Involved in Hirschsprung Associated Enterocolitis Susceptibility through an Altered Downstream Signaling. Int J Mol Sci. 2021; 22(8):3831.
Search in Google Scholar Back to article
Kim WM, Kaser A, Blumberg RS. A role for oncostatin M in inflammatory bowel disease. Nat Med. 2017; 23(5):535-536.
Search in Google Scholar Back to article
West NR, Hegazy AN, Owens BMJ, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017; 23(5):579-589.
Search in Google Scholar Back to article
Mozaffarian A, Brewer AW, Trueblood ES, et al. Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol. 2008; 181(10):7243-53.
Search in Google Scholar Back to article
Datsi A, Steinhoff M, Ahmad F, et al. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy. 2021; 76(10):2982-2997.
Search in Google Scholar Back to article
Tseng PY, Hoon MA. Oncostatin M can sensitize sensory neurons in inflammatory pruritus. Sci Transl Med. 2021; 13(619):eabe3037.
Search in Google Scholar Back to article
Hashimoto T, Nattkemper LA, Kim HS, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. 2021; 30(6):804-810.
Search in Google Scholar Back to article
Stifano G, Sornasse T, Rice LM, et al. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2018; 70(6):912-919.
Search in Google Scholar Back to article
Han L, Yan J, Li T, et al. Multifaceted oncostatin M: novel roles and therapeutic potential of the oncostatin M signaling in rheumatoid arthritis. Front Immunol. 2023; 14:1258765.
Search in Google Scholar Back to article
Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004; 5(7):752-60.
Search in Google Scholar Back to article
Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016; 174(2):296-304.
Search in Google Scholar Back to article
Targoff IN, Miller FW, Medsger TA Jr, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997; 9(6):527-35.
Search in Google Scholar Back to article
Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86.
Search in Google Scholar Back to article
Heinrich PC, Behrmann I, Haan S, et al. Principles of interleu-kin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003; 374(Pt 1):1-20.
Search in Google Scholar Back to article
Lin YZ, Li RN, Lin CH, et al. Association of OSMR gene polymorphisms with rheumatoid arthritis and systemic lupus erythematosus patients. Autoimmunity. 2014; 47(1):23-6.
Search in Google Scholar Back to article
Hong IK, Eun YG, Chung DH, et al. Association of the on-costatin m receptor gene polymorphisms with papillary thyroid cancer in the Korean population. Clin Exp Otorhinolaryngol. 2011; 4(4):193-8.
Search in Google Scholar Back to article
Deng S, He SY, Zhao P, et al. The role of oncostatin M receptor gene polymorphisms in bladder cancer. World J Surg Oncol. 2019; 17(1):30.
Search in Google Scholar Back to article
Dai X, Peng Y, Zhou B, et al. [Association of OSMR gene polymorphisms with dilated cardiomyopathy in a Han Chinese population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2018; 35(2):210-214.
Search in Google Scholar Back to article
Dai X, South AP, Hans-Filho G, et al. Oncostatin M receptor-beta mutations underlie familial primary localized cutaneous amyloidosis. Am J Hum Genet. 2008; 82(1):73-80.
Search in Google Scholar Back to article
Tanaka A, Arita K, Lai-Cheong JE, et al. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol. 2009; 161(6):1217-24.
Search in Google Scholar Back to article
Sharma M, Samra S, Liu Y, et al. Human germline biallelic loss-of-function OSMR variants cause severe allergic disease. [Preprint]. 2025 Aug 8:2025.08.05.25332527. doi: 10.1101/2025.08.05.25332527.
Search in Google Scholar Back to article
Hojman P, Dethlefsen C, Brandt C, et al. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am J Physiol Endocrinol Metab. 2011; 301(3):E504-10.
Search in Google Scholar Back to article
Lacreusette A, Nguyen JM, Pandolfino MC, et al. Loss of on-costatin M receptor beta in metastatic melanoma cells. Oncogene. 2007; 26(6):881-92.
Search in Google Scholar Back to article
Zhong Y, Li J, Zhang Y, et al. The polymorphisms of oncostatin M receptor gene associated with increased risk of lung cancer. Int J Clin Exp Med 2018; 11(11):12421-12428.
Search in Google Scholar Back to article
Miles SA, Martínez-Maza O, Rezai A, et al. Oncostatin M as a potent mitogen for AIDS-Kaposi’s sarcoma-derived cells. Science. 1992; 255(5050):1432-4.
Search in Google Scholar Back to article
Louthrenoo W, Kasitanon N, Mahanuphab P, et al. Kaposi’s sarcoma in rheumatic diseases. Semin Arthritis Rheum. 2003; 32(5):326-33.
Search in Google Scholar Back to article